IP Library Granted Patent US 8,133,685
Granted Patent B2
US 8,133,685 · App. 12/384,446 · Granted Mar 13, 2012

AMPK modulation as a method of regulating stem cell and cancer stem cell proliferation, self-renewal and differentiation

Assignee: Washington University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,133,685
App. No.
12/384,446
Granted
Mar 13, 2012
Kind
B2
Abstract

Methods are disclosed for decreasing stem cell proliferation, including cancer stem cell proliferation. These methods comprise administering to stem cells inhibitors of AMP activated protein kinase (AMPK). Methods for promoting stem cell growth by increasing stem cell proliferation, self-renewal and/or differentiation are also disclosed. These methods comprise administering AMPK activators to stem cells. Methods of achieving selective differentiation of stem cells are also disclosed. These methods comprise administering small molecules to stem cells that modulate AMPK activity. Applications of these methods are also disclosed, such as methods of increasing numbers of neuronal progenitor cells. These methods can be used therapeutically, such as for repair of spinal cord injuries, or for stimulating neurogenesis in the hippocampus, and other cell-based therapies. The methods can also be used for screening of compounds that can be activators or inhibitors of AMPK activity.

Claims (20)

1. A method of screening a compound for activity as an AMPK activator, the method comprising:

providing a cell culture comprising neural stem cells expressing a) AMPK and b) a polypeptide comprising an Rb phosphorylation site;

contacting the cells with a candidate compound; and

detecting an increase in phosphorylation of the Rb phosphorylation site,

whereby an increase in Rb phosphorylation indicates that the compound may be an AMPK activator.

2. A method of screening a compound for activity as an AMPK activator in accordance with claim 1 , wherein the polypeptide comprising an Rb phosphorylation site comprises amino acid sequence ISPLKSPYKI (SEQ ID NO.: 1).

3. A method of screening a compound for activity as an AMPK activator in accordance with claim 1 , wherein the detecting an increase in phosphorylation of the Rb phosphorylation site comprises contacting the polypeptide with an antibody against the polypeptide comprising the Rb phosphorylation site.

4. A method of screening a compound for activity as an AMPK activator in accordance with claim 3 , wherein the antibody against the polypeptide comprising the Rb phosphorylation site is a phospho-specific antibody.

5. A method of screening a compound for activity as an AMPK activator in accordance with claim 3 , wherein the antibody is an antibody against pRbSer 800/804 .

6. A method of screening a compound for activity as an AMPK activator in accordance with claim 3 , wherein the antibody against the polypeptide comprising the Rb phosphorylation site is a pan antibody.

7. A method of screening a compound for activity as an AMPK inhibitor, the method comprising:

providing a cell culture comprising neural stem cells expressing a) AMPK and b) a polypeptide comprising an Rb phosphorylation site;

contacting the cells with a candidate compound; and

detecting a decrease in phosphorylation of the Rb phosphorylation site,

whereby a decrease in Rb phosphorylation indicates that the compound may be an AMPK inhibitor.

8. A method of screening a compound for activity as an AMPK inhibitor in accordance with claim 7 , wherein the polypeptide comprising an Rb phosphorylation site comprises amino acid sequence ISPLKSPYKI (SEQ ID NO.: 1).

9. A method of screening a compound for activity as an AMPK inhibitor in accordance with claim 7 , wherein the detecting an decrease in phosphorylation of the Rb phosphorylation site comprises contacting the polypeptide with an antibody against the polypeptide comprising the Rb phosphorylation site.

10. A method of screening a compound for activity as an AMPK inhibitor in accordance with claim 9 , wherein the antibody against the polypeptide comprising the Rb phosphorylation site is a phospho-specific antibody.

11. A method of screening a compound for activity as an AMPK inhibitor in accordance with claim 9 , wherein the antibody is an antibody against pRbSer 800/804 .

12. A method of screening a compound for activity as an AMPK inhibitor in accordance with claim 9 , wherein the antibody against the polypeptide comprising the Rb phosphorylation site is a pan antibody.

Assignments (2)
CONFIRMATORY LICENSE Recorded Mar 30, 2017
From: WASHINGTON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042114/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 24, 2009
From: MILBRANDT, JEFFREY; DASGUPTA, BIPLAB
To: WASHINGTON UNIVERSITY
Reel/Frame 023561/0638 →
Continuity (2)
Provisional Application 61042253 · Apr 3, 2008
Related Publication 20100221748A1 · Sep 2, 2010